Caregen Co.Ltd Total Liabilities
Caregen Co.Ltd total liabilities. Based on the latest financial reports, Caregen Co.Ltd (214370) has total liabilities worth ₩17.10 Billion KRW (≈ $11.59 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of Caregen Co.Ltd to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Caregen Co.Ltd (2015–2024)
Total liabilities of Caregen Co.Ltd from 2015 to 2024. This chart illustrates how Caregen Co.Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore Caregen Co.Ltd long-term investment allocation to see how much of total assets are deployed in long-term investments.
Caregen Co.Ltd Competitors by Total Liabilities
The table below lists competitors of Caregen Co.Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Bulten AB
ST:BULTEN
|
Sweden | Skr2.68 Billion |
|
Muramoto Electron (Thailand) Public Company Limited
BK:METCO
|
Thailand | ฿2.81 Billion |
|
Newbury Street II Acquisition Corp Class A Ordinary Shares
NASDAQ:NTWO
|
USA | $6.16 Million |
|
Universal Microelectronics Co Ltd
TW:2413
|
Taiwan | NT$2.43 Billion |
|
Eco Atlantic Oil & Gas Ltd
V:EOG
|
Canada | CA$1.26 Million |
|
NINtec Systems Limited
NSE:NINSYS
|
India | Rs527.45 Million |
|
Kobay Tech Bhd
KLSE:6971
|
Malaysia | RM255.47 Million |
Liability Composition Analysis (2015–2024)
This chart breaks down Caregen Co.Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see 214370 current and non-current assets.
Liquidity & Leverage Metrics
Caregen Co.Ltd Total Liabilities Ratios Explained
Caregen Co.Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 13.01 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.08 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Caregen Co.Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Caregen Co.Ltd (2015–2024)
The table below shows the annual total liabilities of Caregen Co.Ltd from 2015 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩17.72 Billion ≈ $12.01 Million |
-11.31% |
| 2023-12-31 | ₩19.98 Billion ≈ $13.54 Million |
+10.43% |
| 2022-12-31 | ₩18.09 Billion ≈ $12.26 Million |
+6.16% |
| 2021-12-31 | ₩17.04 Billion ≈ $11.55 Million |
+49.55% |
| 2020-12-31 | ₩11.40 Billion ≈ $7.72 Million |
-23.20% |
| 2019-12-31 | ₩14.84 Billion ≈ $10.06 Million |
+4.61% |
| 2018-12-31 | ₩14.18 Billion ≈ $9.61 Million |
-6.65% |
| 2017-12-31 | ₩15.19 Billion ≈ $10.30 Million |
+1.14% |
| 2016-12-31 | ₩15.02 Billion ≈ $10.18 Million |
+96.52% |
| 2015-12-31 | ₩7.65 Billion ≈ $5.18 Million |
-- |
About Caregen Co.Ltd
Caregen Co., Ltd. engages in the research, development, and commercialization of biomimetic peptides and growth factors worldwide. The company offers cosmeceutical products and food supplements under the Dermaheal, Renokin, Deglusterol, PURILUX, Pelo Baum, Pim-Pim-Paul, Neovert, and PTx brands. It also provides medical devices under the REVOFIL, DR.CYJ, PROSTROLANE, PROSTROLANE B-Series, and CG S… Read more